• Mohammed R S Keshtgar, Jayant S Vaidya, Jeffrey S Tobias, Frederik Wenz, David Joseph, Chris Stacey, Marinos G Metaxas, Anke Keller, Tammy Corica, Norman R Williams, and Michael Baum.
• Royal Free and University College Medical School, University College London/University College Hospital, London, United Kingdom. m.keshtgar@ucl.ac.uk
• Int. J. Radiat. Oncol. Biol. Phys. 2011 May 1; 80 (1): 31-8.

PurposeExternal beam radiation therapy (EBRT) following wide local excision of the primary tumor is the standard treatment in early breast cancer. In some circumstances this procedure is not possible or is contraindicated or difficult. The purpose of this study was to determine the safety and efficacy of targeted intraoperative radiotherapy (TARGIT) when EBRT is not feasible.Methods And MaterialsWe report our experience with TARGIT in three centers (Australia, Germany, and the United Kingdom) between 1999 and 2008. Patients at these centers received a single radiation dose of 20 Gy to the breast tissue in contact with the applicator (or 6 Gy at 1-cm distance), as they could not be given EBRT and were keen to avoid mastectomy.ResultsEighty patients were treated with TARGIT. Reasons for using TARGIT were 21 patients had previously received EBRT, and 31 patients had clinical reasons such as systemic lupus erythematosus, motor neuron disease, Parkinson's disease, ankylosing spondylitis, morbid obesity, and cardiovascular or severe respiratory disease. Three of these patients received percutaneous radiotherapy without surgery; 28 patients were included for compelling personal reasons, usually on compassionate grounds. After a median follow-up of 38 months, only two local recurrences were observed, an annual local recurrence rate of 0.75% (95% confidence interval, 0.09%-2.70%).ConclusionsWhile we await the results of the randomized trial (over 2,000 patients have already been recruited), TARGIT is an acceptable option but only in highly selected cases that cannot be recruited in the trial and in whom EBRT is not feasible/possible.Copyright © 2011 Elsevier Inc. All rights reserved.

23 keywords...

hide…